Daily Stock Analysis, GENE, Genetic Technologies Ltd, priceseries

Genetic Technologies Ltd. Daily Stock Analysis
Stock Information
Open
1.93
Close
1.93
High
1.94
Low
1.93
Previous Close
1.93
Daily Price Gain
0.00
YTD High
6.34
YTD High Date
May 10, 2019
YTD Low
1.56
YTD Low Date
Aug 16, 2019
YTD Price Change
-0.67
YTD Gain
-25.77%
52 Week High
6.34
52 Week High Date
May 10, 2019
52 Week Low
1.56
52 Week Low Date
Aug 16, 2019
52 Week Price Change
-2.71
52 Week Gain
-58.41%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 19. 2017
3.88
Dec 22. 2017
4.42
3 Trading Days
13.91%
Link
LONG
Jan 4. 2018
4.72
Feb 15. 2018
6.74
18 Trading Days
42.89%
Link
LONG
Apr 9. 2018
4.72
Apr 23. 2018
5.10
10 Trading Days
8.09%
Link
LONG
Jul 13. 2018
4.36
Jul 24. 2018
5.01
7 Trading Days
14.88%
Link
LONG
Jan 4. 2019
2.60
Jan 30. 2019
3.30
17 Trading Days
26.75%
Link
Company Information
Stock Symbol
GENE
Exchange
NasdaqCM
Company URL
http://www.gtglabs.com
Company Phone
011613-9415-1135
CEO
Eutillio Buccilli
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001166272
About

Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Description

Genetic Technologies Limited operates as a life science company, specializing in the fields of genetics and genomics primarily in Australia. The company provides genetic testing services to human beings for disease susceptibility, parentage, individual identity, forensics, and sports performance; animals, such as dogs, horses, birds, alpacas, exotics, and zoo animals for parentage, pedigree, traits, and disease susceptibility; and plants for traits and disease susceptibility. It also offers canine reproductive services, as well as involves in licensing its non-coding DNA patents. In addition, the company offers BREVAGen, a diagnostic test that informs clinicians and patients about individual, non-familial, sporadic risk of breast cancer for women where a breast biopsy outcome is indeterminate. The company was formerly known as Duketon Goldfields N.L. and changed its name to Genetic Technologies Limited in August 2000. Genetic Technologies Limited was incorporated in 1987 and is based in Fitzroy, Australia.